NASDAQ:PACB - Pacific Biosciences of California Stock Price, Price Target & More

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences of California (NASDAQ:PACB) announced its quarterly earnings results on Wednesday, May, 2nd. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $19.40 million for the quarter, compared to analyst estimates of $23.97 million. Pacific Biosciences of California had a negative net margin of 105.22% and a negative return on equity of 91.11%. The firm's quarterly revenue was down 22.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.26) earnings per share. View Pacific Biosciences of California's Earnings History.

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pacific Biosciences of California.

2 analysts have issued twelve-month price targets for Pacific Biosciences of California's stock. Their predictions range from $4.00 to $6.80. On average, they anticipate Pacific Biosciences of California's share price to reach $5.40 in the next year. This suggests a possible upside of 45.9% from the stock's current price. View Analyst Ratings for Pacific Biosciences of California.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Pacific Biosciences of California include Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), HTG Molecular Diagnostics (HTGM), Arrayit Corp common stock (ARYC), Aethlon Medical (AEMD), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).

News articles about PACB stock have been trending positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pacific Biosciences of California earned a coverage optimism score of 0.36 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 45.05 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PACB stock can currently be purchased for approximately $3.70.

Pacific Biosciences of California has a market capitalization of $487.94 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences of California employs 456 workers across the globe.

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]